Patent · US Active

Antagonists of IL-17 isoforms and their uses

US10351623B2 · kind B2 · utility

0Cited by

1References

11Claims

0Family size

Assignees

Orega Biotech · FR
Institut National de la Sante et de la Recherche Medicale (INSERM) · FR

Inventors

Gilles Alberici · Francheville, FR
Jeremy Bastid · Craponne, FR
Armand Bensussan · Créteil, FR
Nathalie Bonnefoy · Val-de-Reuil, FR
Jean-Francois Eliaou · Montpellier, FR

Key dates

Filing date	Nov 20, 2017
Grant date	Jul 16, 2019
Priority date	—
Expiry date	Nov 20, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates generally to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.